...
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma.
【24h】

Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma.

机译:原发性胶质母细胞瘤14Q11.2中NDRG2基因的频繁推动者高甲基化和转录下调。

获取原文
获取原文并翻译 | 示例

摘要

The N-myc downstream-regulated gene 2 (NDRG2) at 14q11.2 has been reported to be downregulated in glioblastoma, and NDRG2 overexpression represses glioblastoma cell proliferation in vitro (Deng et al., Int J Cancer 2003;106;342-7). To further address the role of NDRG2 as a candidate tumor suppressor in human gliomas, we analyzed 67 astrocytic tumors (10 diffuse astrocytomas, 11 anaplastic astrocytomas, 34 primary glioblastomas and 12 secondary glioblastomas) for NDRG2 gene mutation, promoter methylation and expression at the mRNA and protein levels. Using real-time reverse transcription PCR analysis, we found decreased NDRG2 mRNA levels in primary glioblastomas as compared to diffuse and anaplastic astrocytomas. Similarly, immunohistochemistry revealed low or absent NDRG2 protein expression in primary glioblastomas. Mutational analysis of the entire NDRG2 coding sequence did not reveal any tumor-associated DNA sequence alterations. However, sequencing of sodium bisulfite-modified DNA identified hypermethylation of the NDRG2 promoter region in 21 of 34 primary glioblastomas (62%). Moreover, NDRG2 promoter hypermethylation was associated with decreased NDRG2 mRNA expression. In contrast to primary glioblastomas, NDRG2 promoter hypermethylation was detected in only 1 of 11 anaplastic astrocytomas (9%) and was absent in 10 diffuse astrocytomas and 12 secondary glioblastomas. Taken together, our data support NDRG2 as a candidate tumor suppressor gene that is epigenetically silenced in the majority of primary glioblastomas, but not in lower grade astrocytomas and secondary glioblastomas.
机译:据报道,14Q11.2的N-MYC下游调节基因2(NDRG2)在胶质母细胞瘤中下调,NDRG2过表达在体外抑制胶质母细胞瘤细胞增殖(Deng等人,int J癌症2003; 106; 342-7 )。为了进一步解决NDRG2作为人胶质瘤中候选肿瘤抑制剂的作用,我们分析了NDRG2基因突变,启动子甲基化和mRNA表达的67个星形细胞肿瘤(10漫反缩星形细胞瘤,11个内粘性星形母细胞质,34个初级胶质细胞瘤和12次副胶质细胞组织)和蛋白质水平。与弥漫性和包膜性星形胶质细胞瘤相比,我们发现使用实时逆转录PCR分析,我们发现原发性胶质细胞母细胞瘤中的NDRG2 mRNA水平降低。类似地,免疫组织化学在原发性胶质细胞组织中揭示了低或不存在的NDRG2蛋白表达。整个NDRG2编码序列的突变分析没有揭示任何肿瘤相关的DNA序列改变。然而,亚硫酸氢钠改性DNA的测序鉴定了34个初级胶质细胞母细胞瘤(62%)中的NDRG2启动子区的高甲基化。此外,NDRG2启动子高甲基化与降低的NDRG2 mRNA表达有关。与原发性胶质细胞组织相比,在11个内塑料星形胶质细胞瘤(9%)中仅检测NDRG2启动子高甲基化,并在10个弥漫性星形细胞瘤和12个副胶质细胞组中。我们的数据支持NDRG2作为候选肿瘤抑制基因,在大多数原发性胶质细胞组织中表现出脑表现出,但不在较低级星形细胞和次生胶质细胞组中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号